Ultragenyx Pharmaceutical Inc. Insider Trading for March 2020
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Ultragenyx Pharmaceutical Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Ultragenyx Pharmaceutical Inc. for March 2020.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 13 2020 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Option Exercise | X | 3.01 | 66,533 | 199,998 | 0 | |
| Mar 13 2020 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Option Exercise | X | 3.01 | 83,167 | 250,000 | 0 | |
| Mar 13 2020 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Buy | X | 3.01 | 66,533 | 199,998 | 654,500 | 588 K to 654.5 K (+11.32 %) |
| Mar 13 2020 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Buy | X | 3.01 | 83,167 | 250,000 | 587,967 | 504.8 K to 588 K (+16.48 %) |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | Harris Erik | EVP & Chief Commerc ... | Option Exercise | A | 56.08 | 22,000 | 1,233,760 | 22,000 | |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | Harris Erik | EVP & Chief Commerc ... | Payment of Exercise | F | 56.08 | 824 | 46,210 | 24,572 | 25.4 K to 24.6 K (-3.24 %) |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | Harris Erik | EVP & Chief Commerc ... | Grant | A | 0.00 | 3,287 | 0 | 25,396 | 22.1 K to 25.4 K (+14.87 %) |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | Harris Erik | EVP & Chief Commerc ... | Grant | A | 0.00 | 7,800 | 0 | 22,109 | 14.3 K to 22.1 K (+54.51 %) |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | Parschauer Karah Herdman | EVP and General Cou ... | Option Exercise | A | 56.08 | 22,000 | 1,233,760 | 22,000 | |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | Parschauer Karah Herdman | EVP and General Cou ... | Payment of Exercise | F | 56.08 | 2,118 | 118,777 | 30,400 | 32.5 K to 30.4 K (-6.51 %) |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | Parschauer Karah Herdman | EVP and General Cou ... | Grant | A | 0.00 | 5,634 | 0 | 32,518 | 26.9 K to 32.5 K (+20.96 %) |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | Parschauer Karah Herdman | EVP and General Cou ... | Grant | A | 0.00 | 7,800 | 0 | 26,884 | 19.1 K to 26.9 K (+40.87 %) |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Option Exercise | A | 56.08 | 56,100 | 3,146,088 | 56,100 | |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Payment of Exercise | F | 56.08 | 6,896 | 386,728 | 504,800 | 511.7 K to 504.8 K (-1.35 %) |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Grant | A | 0.00 | 18,782 | 0 | 511,696 | 492.9 K to 511.7 K (+3.81 %) |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Grant | A | 0.00 | 17,000 | 0 | 492,914 | 475.9 K to 492.9 K (+3.57 %) |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | Huizenga Theodore Alan | SVP, Controller and ... | Option Exercise | A | 56.08 | 7,480 | 419,478 | 7,480 | |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | Huizenga Theodore Alan | SVP, Controller and ... | Payment of Exercise | F | 56.08 | 388 | 21,759 | 17,058 | 17.4 K to 17.1 K (-2.22 %) |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | Huizenga Theodore Alan | SVP, Controller and ... | Grant | A | 0.00 | 1,500 | 0 | 17,446 | 15.9 K to 17.4 K (+9.41 %) |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | Huang Dennis Karl | EVP & Chief Tech Op ... | Option Exercise | A | 56.08 | 22,000 | 1,233,760 | 22,000 | |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | Huang Dennis Karl | EVP & Chief Tech Op ... | Payment of Exercise | F | 56.08 | 1,779 | 99,766 | 35,475 | 37.3 K to 35.5 K (-4.78 %) |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | Huang Dennis Karl | EVP & Chief Tech Op ... | Grant | A | 0.00 | 5,634 | 0 | 37,013 | 31.4 K to 37 K (+17.95 %) |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | Huang Dennis Karl | EVP & Chief Tech Op ... | Grant | A | 0.00 | 7,800 | 0 | 31,379 | 23.6 K to 31.4 K (+33.08 %) |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | Pinion John Richard | See Remarks | Option Exercise | A | 56.08 | 22,000 | 1,233,760 | 22,000 | |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | Pinion John Richard | See Remarks | Payment of Exercise | F | 56.08 | 3,085 | 173,007 | 49,487 | 46.4 K to 49.5 K (+6.65 %) |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | Pinion John Richard | See Remarks | Grant | A | 0.00 | 5,634 | 0 | 52,572 | 46.9 K to 52.6 K (+12.00 %) |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | Pinion John Richard | See Remarks | Grant | A | 0.00 | 7,800 | 0 | 46,938 | 39.1 K to 46.9 K (+19.93 %) |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | Kassberg Thomas Richard | CBO & EVP | Option Exercise | A | 56.08 | 20,000 | 1,121,600 | 20,000 | |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | Kassberg Thomas Richard | CBO & EVP | Payment of Exercise | F | 56.08 | 2,067 | 115,917 | 102,171 | 104.2 K to 102.2 K (-1.98 %) |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | Kassberg Thomas Richard | CBO & EVP | Grant | A | 0.00 | 5,634 | 0 | 104,109 | 98.5 K to 104.1 K (+5.72 %) |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | Kassberg Thomas Richard | CBO & EVP | Grant | A | 0.00 | 6,800 | 0 | 98,475 | 91.7 K to 98.5 K (+7.42 %) |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | Sharp Shalini | CFO & Executive Vic ... | Payment of Exercise | F | 56.08 | 2,325 | 130,386 | 103,832 | 106.2 K to 103.8 K (-2.19 %) |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | Sharp Shalini | CFO & Executive Vic ... | Grant | A | 0.00 | 5,634 | 0 | 106,157 | 100.5 K to 106.2 K (+5.60 %) |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | Bedrosian Camille L | EVP and Chief Medic ... | Option Exercise | A | 56.08 | 21,000 | 1,177,680 | 21,000 | |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | Bedrosian Camille L | EVP and Chief Medic ... | Payment of Exercise | F | 56.08 | 1,249 | 70,044 | 36,300 | 37.5 K to 36.3 K (-3.33 %) |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | Bedrosian Camille L | EVP and Chief Medic ... | Grant | A | 0.00 | 5,634 | 0 | 37,549 | 31.9 K to 37.5 K (+17.65 %) |
| Mar 03 2020 | RARE | Ultragenyx Pharmac ... | Bedrosian Camille L | EVP and Chief Medic ... | Grant | A | 0.00 | 7,300 | 0 | 31,915 | 24.6 K to 31.9 K (+29.66 %) |